The substantial blood draws prescribed by Dr. and Mr. Geier upon entry into their Lupron-chelation study and for ongoing monitoring seem to reflect little consideration of the risk of harm posed to the autistic children who are their research subjects. The test battery also seems to reflect little concern for cost containment or appropriate test sequencing. As noted in the above chart, the total price tag for LabCorp tests included in the Geiers’ eligibility assessment exceeds $10,000; their diagnostic shopping list includes newly developed assays that are not covered by most standard health insurance policies.Significant Misrepresentations: Mark Geier, David Geier & the Evolution of the Lupron Protocol (Contents)
Monday, August 28, 2006
I Feel Faint...
Neurodiversity continues exposing the horrors of the Geiers.